46v9tswsnyusxkeqbnne bih drug safety center

Bayou Institute for Health

No Reviews Yet
No Completed Orders
Houston, Texas, US

About Bayou Institute for Health

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety evaluation and in vivo ADME/DMPK, safety and efficacy. BIH scientists (as well-recognized... Show more »

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety evaluation and in vivo ADME/DMPK, safety and efficacy. BIH scientists (as well-recognized electrophysiology experts) have established and fully validated the patch clamp assays for hERG inhibition and the cardiac multiple ion channel panel as a key component of the CiPA initiative to generate high-quality data for decision‐making during the drug discovery and development process to support drug screening and IND submissions.  

 

Show less

Our Services (5)


ic

hERG Channel Inhibition Assay

Price on request

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety assessment. BIH scientists (as well-recognized electrophysiology experts) have established and fully validated patch clamp-based assays for quantifying hERG... Show more »

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety assessment. BIH scientists (as well-recognized electrophysiology experts) have established and fully validated patch clamp-based assays for quantifying hERG inhibition and kinetics to provide their clients high-quality data for decision‐making during the drug discovery and development process to support drug screening and IND submissions. For further information, please consult with BIH technical support at [email protected] 

BIH Drug Safety Center has provided the clients with the high-quality standard and custom assays for quantifying hERG inhibition and kinetics. They are highlighted as follows.

Regulatory Requirements: GLP-compliant and non-GLP-exploratory platforms
Gold Methods: Electrophysiological patch clamp on HEK293-hERG cells and hiPSC-CMs
Quality Control: Conducted at physiological temperature (37 oC) with positive references
Data Analysis: Standardized batch analysis for stable amplitude and kinetics
Study Summary: IC50 curve, kinetics or inhibition with attached raw data
Regulatory Report: FDA-requested e-report for electronic IND submission
 

Show less
hERG hERG Channel Inhibition Assay Ion Channel Screening Cardiac Safety Assessment ICH S7B in vitro cardiotoxicity Patch Clamp hERG safety Show 8 more tags Show less

ic

Ion Channel Screening Assays

Price on request

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety assessment. BIH scientists (as well-recognized electrophysiology experts) have established and fully validated electrophysiologic patch clamp-based protocols for... Show more »

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety assessment. BIH scientists (as well-recognized electrophysiology experts) have established and fully validated electrophysiologic patch clamp-based protocols for assessing hERG inhibition/ kinetics and the cardiac multiple ion channel panel as a key component of the CiPA initiative; and employed them to provide their clients high-quality data for decision‐making during the drug discovery and development process to support drug screening and IND submissions.

BIH Cardiac Multiple Ion Channel Panel is considered as a key component of the Comprehensive In Vitro Proarrhythmia Assay (CiPA); and composed of voltage-gated Cav1.2 (ICa,L), Nav1.5 (INa), Kv11.1 (hERG, IKr), Kir2.1 (IK1), Kv1.5 (IKur), Kv4.3 (ITO), and KvLQT1/minK (IKs). Notably, this panel is crucial when hERG inhibition is positive and recommended for drug discovery and early drug development. For further information, please consult with BIH technical support at [email protected] 

Show less
Safety Pharmacology hERG Ion Channel Screening Cardiac Safety Assessment Ion channel profiling Patch Clamp cardiac channel assays action potential Show 8 more tags Show less

ic

In silico Cardiac Safety Assessment

Price on request

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety assessment. BIH scientists (as well-recognized electrophysiology experts) have established and fully validated in vitro assays for quantifying the cardiac hERG... Show more »

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical in vitro cardiac safety assessment. BIH scientists (as well-recognized electrophysiology experts) have established and fully validated in vitro assays for quantifying the cardiac hERG (Ikr) inhibition/ kinetics and the cardiac multiple ion channel panel as a key component of the CiPA initiative; and employed them to provide their clients high-quality data for decision‐making during the drug discovery and development process to support drug screening and IND submissions. For further information, please consult with BIH technical support at [email protected]

Show less
hERG Channel Inhibition Assay Ion Channel Screening Cardiac Safety Assessment Ion channel profiling in vitro cardiotoxicity Patch Clamp cardiac channel assays in vitro cardiotoxicity screening Show 8 more tags Show less

ic

Stable Isotope Analysis

Price on request

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical metabolomics, an innovative platform for drug discovery and metabolic profiling. Our scientists assist researchers to quantify stable isotope 13C metabolic fluxes of macronutrients... Show more »

Bayou Institute for Health (BIH) Drug Safety Center (www.bayous.org) has provided high-quality nonclinical services with focus on nonclinical metabolomics, an innovative platform for drug discovery and metabolic profiling. Our scientists assist researchers to quantify stable isotope 13C metabolic fluxes of macronutrients (glucose, fatty acids, amino acids) and bile acids using stable isotopic tracers continuously infused in humans and animals. It is vital to characterize de novo synthesis of glucose, fatty acids and proteins, metabolic reprogramming of key energy fuels (such as glucose and amino acids), and tissue-specific insulin sensitivity in response to intakes of drugs or nutrients. For example, we quantify tissue-specific insulin sensitivity in stress-free, conscious mice with hyperinsulinemic euglycemic clamp coupled with stable isotopic tracers (2H2O and 6,6-2H2-d-glucose), a gold method for the assessment of endogenous glucose production and glucogenesis. For further information, please consult with BIH technical support at [email protected]

Show less
Metabolite Profiling in vivo metabolism stable isotope tracers insulin sensitivity in vivo metabolic fluxes glucose production glucose metabolism Show 7 more tags Show less

ic

In vivo ADME/DMPK Studies

Price on request

BIH Drug Safety Center (www.bayous.org) has performed in vivo drug metabolism studies for over 20 years; and our domestic partners’ laboratories have provided in vivo pharmacology and toxicology services for more than 40 years. We are committed to providing excellent services on... Show more »

BIH Drug Safety Center (www.bayous.org) has performed in vivo drug metabolism studies for over 20 years; and our domestic partners’ laboratories have provided in vivo pharmacology and toxicology services for more than 40 years. We are committed to providing excellent services on comprehensive nonclinical ADME/ DMPK and toxicology in good laboratory practice (GLP)-compliant or non‐GLP-exploratory platforms to assess drug metabolism and safety early in the drug discovery/ development process and generate high-quality data to meet regulatory requirements of Investigational New Drug (IND) applications. For further information, please consult with BIH technical support at [email protected]

 

Show less
Safety Pharmacology pharmacokinetics toxicokinetic in vivo ADME/DMPK Studies pharmacodynamics

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.

Bayou Institute for Health has not received any reviews.

Bayou Institute for Health has not received any endorsements.